ENZO BIOCHEM INC

ENZB

Explore Our Financial Data > Companies > ENZO BIOCHEM INC

Identification

Click on a field for details on how to access that data via Web API, Excel, or CSV Download.

Ticker	ENZB
CIK	0000316253
SIC	8071
Sector	Services
Industry Category	Healthcare
Industry Group	Services – Health

Contact

Address	60 EXECUTIVE BLVD, FARMINGDALE, NY, 11735
Website	enzo.com
Phone	5167555500
CEO	Hamid Erfanian
Employees	520

Access This Data

Our team will help you customize a package that meets the needs of your business.

Request a Consultation

Standardized Financials

docs

Intrinio provides professional-grade historical financial data. This data is standardized, cleansed and verified to ensure the highest quality data sourced directly from the XBRL financial statements. The primary purpose of standardized financials are to facilitate comparability across a single company’s fundamentals and across all companies fundamentals.

For example, it is possible to compare total revenues between two companies as of a certain point in time, or within a single company across multiple time periods. This is not possible using the as reported financial statements because of the inherent complexity of reporting standards.

Below is a preview of several data points from each financial statement, as well as a sample of our many calculated metrics:

Income Statement

Revenue	$29.10 million
Pre-Tax Income	$-7.60 million
Net Income	$-21.31 million
Net Income to Common	$-21.31 million
EPS	$-0.42

View All

Balance Sheet

Cash	$40.30 million
Assets	$67.51 million
Liabilities	$20.89 million
Common Equity	$46.62 million
Liabilities & Equity	$67.51 million

View All

Cash Flow Statement

Net Income	$-21.31 million
Cash From Operating Activities	$-14.96 million
Cash From Investing Activities	$4.22 million
Cash From Financing Activities	$-9.18 million
Change in Cash	$-19.94 million

View All

Calculations

NOPAT	$-6.95 million
EBITDA	$-8.78 million
Price to Earnings	N/A
Price to Book	N/A
ROE	-36.31%

View All

Latest News

docs

Intrinio provides up-to-date news articles on every US company from various sources. Here are several examples:

Enzo Biochem, Inc. Announces Review of Strategic Alternatives after Receiving Multiple Inquiries Regarding a Potential Transaction

Forms Special Committee of the Board to Lead Evaluation of Viable Options for Maximizing Shareholder Value Engages Independent Financial and Legal Advisors to Support Thorough Process Remains Committed to Maintaining Focus on Cost Containment, Cash Preservation and Near-Term Initiatives to Enhance Value Farmingdale, NY, April 22, 2025 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (OTCQX: ENZB) (“Enzo” or the “Company”) today announced that its Board of Directors (the “Board”) has commenced a review of

Article Link

The Zacks Analyst Blog AbbVie, The TJX, The Charles Schwab, Enzo Biochem and CVD Equipment

AbbVie, The TJX, The Charles Schwab, Enzo Biochem and CVD Equipment are included in this Analyst Blog.

Article Link

Top Research Reports for AbbVie, TJX & Charles Schwab

Today's Research Daily features new research reports on 16 major stocks, including AbbVie Inc. (ABBV), The TJX Companies, Inc. (TJX) and The Charles Schwab Corporation (SCHW), as well as two micro-cap stocks, Enzo Biochem, Inc. (ENZ) and CVD Equipment Corporation (CVV).

Article Link

Enzo Biochem Announces Notification to New York Stock Exchange of Intention to Voluntarily Delist Common Stock and Transfer Trading of Shares to OTCQX

FARMINGDALE, N.Y., March 28, 2025 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”) today announced its intention to voluntarily delist its common stock from The New York Stock Exchange (“NYSE”) and to have its common stock quoted on the OTCQX Best Market (“OTCQX”). Enzo provided notice of the voluntary delisting to the NYSE on March 28, 2025 and intends to timely file a notification of removal from listing on Form 25 with the Securities and Exchange Commission (the “S

Article Link

Here’s Why Enzo Biochem (ENZ) Declined in Q4

Kingdom Capital Advisors, a private investment firm, released its fourth-quarter 2024 investor letter. A copy of the letter can be downloaded here. Kingdom Capital Advisors is in its third year of operation as of the end of 2024. Since the firm’s inception, small cap stocks, as determined by the Russell 2000 TR, have experienced a […]

Article Link